STAT+: Relay discloses encouraging results for experimental breast cancer treatment

Relay Therapeutics disclosed encouraging results for its key breast cancer drug and plans to advance the experimental treatment, called RLY-2608, to a late-stage clinical trial, the biotech firm said on Monday.

The new data come from an open label phase 1/2 trial on RLY-2608 combined with fulvestrant, an endocrine therapy for breast cancer, showing a third of patients with measurable disease responded to the treatment. The data were put out in a press release from Cambridge, Mass.-based Relay, and haven’t been published in a peer reviewed journal.

RLY-2608 works on cancers that carry mutations in a gene called PIK3CA, which encodes a piece of the PI3K-alpha protein. This molecular pathway helps to control cell growth and division, and errors in it can drive a variety of cancers including breast cancer. It’s one of the most common mutations driving cancers and is implicated in 20% to 40% of breast cancer cases. 

Continue to STAT+ to read the full story…